Description du projet
Pancréas artificiel: une meilleure thérapie pour les enfants atteints de diabète
Le diabète de type 1 chez l’enfant peut avoir plusieurs conséquences sur la santé. Par conséquent, il nécessite un contrôle minutieux de la glycémie. Les pompes à insuline délivrent un apport continu d’insuline tout au long de la journée, mais l’utilisateur doit ajuster le dosage en fonction de sa glycémie. En revanche, un pancréas artificiel est un système en boucle fermée qui mesure automatiquement la glycémie et calcule le dosage approprié. Le projet KidsAP, financé par l’UE, étudiera l’efficacité d’un pancréas artificiel chez des enfants âgés de 1 à 7 ans atteints de diabète de type 1. Les chercheurs compareront le dispositif à la thérapie par pompe à insuline standard, en évaluant la qualité de vie et en menant des entretiens. Ces résultats devraient permettre d’améliorer les soins de santé pour les jeunes enfants souffrant de cette maladie.
Objectif
TYPE 1 DIABETES is one of the most COMMON CHRONIC diseases in children with a RAPID increase in number of cases particularly in young children. Type 1 diabetes is associated with LIFE-LONG dependency on insulin administration. POOR glucose control leads to diabetes COMPLICATIONS, e.g. eye, heart, kidney disease, including BRAIN changes in young children. Episodes of VERY LOW glucose levels may be life threatening and are a major complication.
The ARTIFICIAL PANCREAS addresses the problem of LOW and HIGH glucose levels by delivering insulin BELOW and ABOVE pre-set amounts according to real-time sensor GLUCOSE levels, combining glucose SENSOR, insulin PUMP, and CONTROL ALGORITHM. The Artificial pancreas promises to TRANSFORM management of type 1 diabetes but EVIDENCE supporting its use during FREE LIVING in YOUNG CHILDREN is MISSING.
The project evaluates the biomedical, psychosocial, and cost effectiveness of NOVEL INDIVIDUALISED artificial pancreas in young children aged 1 to 7 years with type 1 diabetes. Following a PILOT (n=24), in the MAIN study (n=94) half of the participants (n=47) will be treated over 12 MONTHS by the ARTIFICIAL PANCREAS and the other half (n=47) by STATE-OF-THE-ART PREDICTIVE LOW GLUCOSE MANAGEMENT insulin pump therapy. Each treatment will last ONE YEAR. QUALITY OF LIFE will be assessed and semi-structured INTERVIEWS conducted to understand the impact on daily life. HEALTH TECHNOLOGY ASSESSMENT will support reimbursement.
The project will OPTIMISE artificial pancreas and SPEARHEAD SYSTEM-WIDE improvements in health care quality and health outcomes in YOUNG CHILDERN with TYPE 1 DIABETES who live with the disease LONGEST. By IMPROVING THERAPEUTIC OUTCOMES, the project will CHANGE clinical practice and INFLUENCE national and international treatment guidelines making the artificial pancreas WIDELY ACCEPTABLE as the state-of-art treatment modality in young children.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
CB2 1TN Cambridge
Royaume-Uni